Peptide Testing Daily: 28 October 2026

Posted in Uncategorized

New public test results since the last issue. Source: Finnrick’s public data summary, latest test 21 Oct 2026. Results are information, not endorsements or medical advice.

The headline

2 new tests across 2 peptides. Running total: 12,622 tests on 35 peptides, 70% passing Finnrick’s default standard.

New results by peptide

PeptideNew testsPassedFailedAll testsOverall pass rate
Retatrutide1004,65177%
Wolverine12-212too few
Pass rate = passed / (passed + failed) under Finnrick’s Purity Focus standard; tests with incomplete data are excluded. Overall pass rates are shown only for peptides with at least 70 tests. Click a peptide for its full record on Finnrick.

Comment

  • Most new results were for Retatrutide (1 tests).
  • Wolverine’s overall pass rate rose from 0% to 25%.
  • Reminder: a pass means the powder matched its label on the day it was tested (purity at least 99.5%, fill within 35%). It says nothing about endotoxin unless that test was ordered, and nothing about a different batch.

How to check a certificate, and what each test measures: Peptide Testing.

genetec.io does not sell peptides, recommend vendors or link to shops. Most of these products are not registered medicines in South Africa or the United States; speak to a registered doctor before using any of them.

South Africa’s regulators and the black-market weight-loss jabs

admin
Posted in Uncategorized

A summary of “SA’s regulators are struggling to keep up with black-market weight-loss jabs” by Linda Nordling (Daily Maverick and Bhekisisa, 23 October 2026), with the legal background. Information, not medical or legal advice.

What the article reports

  • A court order. In June 2026 the Gauteng High Court ordered iDexis, a compounding pharmacy in Tshwane, to stop making medicine containing semaglutide, the active ingredient of Ozempic. Large quantities of compounded jabs had been confiscated from its premises.
  • A generic. The first generic semaglutide reached South African pharmacies in August 2026.
  • An unlicensed drug sold openly. Retatrutide is still in clinical trials and is not licensed anywhere, yet it is sold “openly and brazenly”, according to Stavros Nicolaou of the Pharmaceutical Task Group.
  • Informal channels. SAHPRA has received about 600 complaints this financial year about medicines sold through online portals, gyms and hairdressers. Some active ingredients have reportedly arrived in travellers’ luggage.
  • A doctor as seller. A Johannesburg woman’s doctor sold her retatrutide, said he “had it tested”, and had her sign a waiver.
  • Slow rules. Revised compounding guidelines, led by SAHPRA, are not expected before February or March 2027. Australia has already banned pharmacy compounding of weight-loss jabs.

The legal background

  • Compounding is not a route to new drugs. Section 14(4) of the Medicines Act lets a pharmacist compound a medicine without registering it, but the active ingredient must appear in a medicine that has been registered. A drug still in trials, such as retatrutide, or one never registered, such as BPC-157, cannot be compounded lawfully.
  • Compounding is for individual patients. SAHPRA and the Pharmacy Council said in May 2026 that compounding is strictly limited to medicines prepared for individual patients on a valid prescription. Large-scale production is manufacturing and needs a manufacturing licence.
  • Compounded GLP-1s may be banned outright. In March 2025 SAHPRA announced its intention to declare compounded GLP-1 and GLP-1/GIP medicines (semaglutide, tirzepatide) undesirable under section 23 of the Act. Once declared, no one may sell them. As of the latest report we found (May 2026), the declaration had not yet been made.
  • Making these medicines at scale needs a manufacturing licence for that kind of product. SAHPRA licenses manufacturers for specific products and dosage forms under good manufacturing practice (GMP). An injection must be made sterile, which needs clean rooms, validated sterile filling and endotoxin control, and a licence that covers sterile products. A site licensed to make a non-sterile product, such as an oral oil, cannot simply switch to injections. A licence also does not permit the sale of an unregistered product: what a licensed manufacturer sells must be registered, or supplied for a named patient under Section 21.
  • The lawful route to an unregistered medicine is Section 21: a doctor applies to SAHPRA for one named patient, naming the product and an authorised supplier, and reports the outcome within six months.

Comment

  • The regulator’s advice is the right question. SAHPRA’s Daphne Fafudi: “If you cannot trust the source, do not trust the medicine.” The question is how a buyer can trust a source.
  • Packaging checks are necessary, not sufficient. SAHPRA’s warning signs (blank or unusual packaging, no expiry date, no package insert, damaged packaging) catch careless fakes. A careful counterfeiter prints a proper box.
  • A seller’s test is the seller’s word. “I had it tested” means nothing unless the certificate names the batch in your hand and can be checked at the issuing lab. The worldwide test data we summarise every day shows that about one vial in three fails its label (Peptide Testing).
  • Cheap legal supply is the strongest answer. With generic semaglutide now on the shelf, a prescription from a registered doctor is the safest route for anyone who needs this medicine.

genetec.io does not sell medicines or peptides, recommend vendors or link to shops. Speak to a registered doctor before using any of these products. To report a suspicious medicine, contact SAHPRA.

Peptide Testing Daily: 24 October 2026

Posted in Uncategorized

First issue: a baseline. From tomorrow, each issue reports what changed since the day before. Source: Finnrick’s public data summary, snapshot of 21 October 2026. Results are information, not endorsements or medical advice.

The headline

Finnrick has published 12,626 independent tests across 35 peptides and 499 vendors, 709 of them in the last four weeks. Of the tests that could be scored, 70% passed its default standard (purity at least 99.5%, fill within 35% of the label) and 30% failed. Roughly one vial in three does not match its label to that standard.

Pass rates by product

PeptideTestsPass rateVendors testedLatest test
GHK-Cu1,00186%15320 Oct
Tirzepatide2,84578%27720 Oct
Retatrutide4,65677%40721 Oct
Ipamorelin45468%9312 Oct
Semaglutide38167%7412 Oct
PT-141 (bremelanotide)15765%4612 Oct
Melanotan II18362%4512 Oct
Cagrilintide20754%4620 Oct
BPC-15793850%14921 Oct
Tesamorelin74348%11320 Oct
TB-50029339%6020 Oct
MOTS-c8734%2212 Oct
CJC-129533729%7015 Oct
NAD+7124%2112 Oct
Products with at least 70 published tests. Pass rate = passed / (passed + failed) under Finnrick’s Purity Focus standard; tests with incomplete data are excluded. Click a peptide for its full record on Finnrick.

Comment

  • The big sellers test best. The two most-tested peptides, retatrutide and tirzepatide, pass about 77–78% of the time. High volume brings more testing, and testing pushes quality up.
  • The “healing” peptides test worst. BPC-157 passes only half the time, TB-500 under 40%, CJC-1295 under 30%. These are among the most popular peptides with the weakest clinical evidence, so the buyer is uncertain about both the product and the science.
  • A fail is not always a bad product, and a pass is not a safe one. The 99.5% purity bar is strict, so many failures are underfilled or slightly impure vials rather than the wrong substance. And none of these figures include endotoxin, which is the main danger in an injection and is only tested when someone pays for it.
  • One batch is one batch. A seller’s pass rate tells you about past batches. Only the certificate for the batch in your hand, checked at the issuing lab, tells you about that vial.

How to check a certificate, and what each test measures: Peptide Testing.

genetec.io does not sell peptides, recommend vendors or link to shops. Most of these products are not registered medicines in South Africa or the United States; speak to a registered doctor before using any of them.

The Bioelectric Symphony: Unveiling the Electrical Secrets of Life

admin
Posted in Uncategorized

The Bioelectric Symphony: Unveiling the Electrical Secrets of Life

Life is often described as a complex dance of chemical reactions, but there’s another layer of intricacy at play: bioelectricity. This fascinating phenomenon, where living organisms generate and utilize electrical signals, is fundamental to how our bodies function, from the smallest cells to the largest multicellular organisms. This blog post will delve into the world of the bioelectric layer, exploring what it is, how it works, and its significance in the grand scheme of biology and technology.

What is the Bioelectric Layer?

The bioelectric layer refers to the electrical potential differences that exist across the membranes of cells and tissues within living organisms. These electrical potentials arise from the movement of ions (charged atoms or molecules) across cell membranes. This movement is carefully regulated by specialized proteins, creating a charge separation that can be harnessed for various biological functions. Essentially, it’s a network of tiny batteries within us, powering everything from nerve impulses to wound healing.

How Does the Bioelectric Layer Work?

The foundation of the bioelectric layer lies in the selective permeability of cell membranes. These membranes act as insulators, separating the intracellular and extracellular environments. Embedded within these membranes are ion channels and pumps, which are proteins that control the flow of ions like sodium (Na+), potassium (K+), chloride (Cl-), and calcium (Ca2+). These channels can open or close in response to various stimuli, allowing ions to move across the membrane.

Ion pumps, such as the sodium-potassium pump, actively transport ions against their concentration gradients, creating and maintaining the electrochemical gradients necessary for electrical signaling. This creates a difference in charge across the membrane, known as the resting membrane potential. When a cell is stimulated, ion channels open, allowing ions to flow down their electrochemical gradients, leading to changes in the membrane potential. These changes can propagate along the cell membrane, generating electrical signals.

Examples of the Bioelectric Layer in Nature

The bioelectric layer is a fundamental aspect of life, and its influence can be seen across the biological spectrum. Here are a few examples:

* Nerve Impulses: Perhaps the most well-known example is the transmission of nerve impulses. Neurons use electrical signals to transmit information throughout the nervous system. These signals, called action potentials, are generated by the rapid influx and efflux of ions across the neuron’s membrane.

* Muscle Contraction: Muscle cells also rely on bioelectricity. The arrival of an electrical signal triggers the release of calcium ions, which initiates the process of muscle contraction.

* Wound Healing: Bioelectric fields play a crucial role in wound healing. Damaged tissues generate electrical signals that attract cells involved in repair and regeneration.

* Embryonic Development: During embryonic development, bioelectric gradients guide cell differentiation and tissue formation.

* Electroreception: Some animals, like sharks and electric eels, have evolved the ability to detect or generate strong electric fields for navigation, hunting, and defense.

Conclusion

The bioelectric layer is a fascinating and essential aspect of life, underpinning a wide range of biological processes. From the rapid communication of nerve impulses to the intricate development of embryos, bioelectricity plays a critical role. As our understanding of this electrical symphony deepens, we can expect to see even more exciting applications in medicine, biotechnology, and beyond. Further research into the bioelectric layer holds the potential to revolutionize fields such as regenerative medicine, bio-integrated devices, and our fundamental understanding of how life works.